Document:

Retirement Agreement by and between David A. Bloss, Sr. and CIRCOR Int'l Inc.

 Exhibit 10.1 
 RETIREMENT AGREEMENT 
 This AGREEMENT (the
“Agreement”) is made as of the 22nd day of August, 2007 (the “Effective Date”), by and between CIRCOR International, Inc., a Delaware
corporation, (the “Company”) and David A. Bloss, Sr. (the “Chairman”). 
 WHEREAS, the Chairman has informed the
Company of his intention to retire on March 1, 2008; and 
 WHEREAS, the Company recognizes the Chairman’s comprehensive knowledge
of the Company and the fluid control industry and, as such, wishes to establish the terms of the Chairman’s continued relationship with the Company after the end of his employment; and 
 WHEREAS, the Company’s Board of Directors (the “Board”) has determined that it is in the best interest of the Company and its shareholders
to assure that the Chairman enter into this Agreement; 
 NOW, THEREFORE, in consideration of the mutual promises and conditions set forth in
this Agreement, the sufficiency of which is hereby acknowledged, the Company and the Chairman agree as follows: 
 1. Transition.
From the Effective Date through and including March 1, 2008 (the “Transition Date”)(collectively, the “Transition Period”), the Chairman will continue to serve as the Company’s Chairman and Chief Executive Officer.
The terms and conditions of his employment during the Transition Period shall be governed by the Executive Employment Agreement by and between the Company and the Chairman dated as of September 16, 1999, as amended and restated
September 10, 2005 (the “Employment Agreement”). The Chairman’s bonus for 2007 will be paid in February, 2008. 
 2.
Retirement. On the Transition Date, the Chairman will retire as an employee of the Company and will resign from any and all other positions that he may hold with the Company (including those with any or all of the Company’s affiliates),
except as a director and as Chairman of the Board. The Chairman and the Company agree that, as of the Transition Date, all salary, bonus, and any other employee compensation otherwise payable to the Chairman will cease, and any benefits the Chairman
has or might have under any Company-provided employee benefit plans, programs, or practices (including, but not limited to participation in group medical, dental and vision plans; short-term and long-term disability insurance; basic and executive
life insurance; basic accidental death and dismemberment insurance; and participation in the employee assistance plan) will terminate, except as required by federal or state law, by the terms of the respective benefit plan, or as otherwise described
in this Agreement. Notwithstanding anything in this Section to the contrary, nothing herein shall terminate the Chairman’s vested rights to receive retirement benefits provided by the Company’s qualified and nonqualified retirement plans
(the “Retirement Plans”). 
 3. Continuation of Group Health Insurance. As of the Transition Date, the Chairman’s
eligibility for health, dental and vision benefits under the Company’s group health 

 
plan ceases. If the Chairman timely elects coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Chairman may
continue his health, dental and vision benefits for a period not to exceed that prescribed under COBRA, as applied to all retirees of the Company. 
 4. Appointment as Non-Employee Chairman. Contingent upon the Chairman being reelected to the Board as a non-employee director by the Company’s shareholders in May, 2008, the Board shall appoint the Chairman as its non-employee
Chairman for a term commencing on March 1, 2008 (the “Commencement Date”) and ending on the Company’s 2009 annual shareholder meeting (such time period is hereinafter referred to as the “Chairmanship Period”). During
the Chairmanship Period, the Chairman shall provide leadership to the Board by, among other things, working with the Chief Executive Officer and the Corporate Secretary to set Board calendars, prepare agendas for Board meetings, ensure proper flow
of information to Board members, facilitate effective operation of Board and Committee work, help promote Board succession planning and the recruitment and orientation of new directors, address issues of director performance, assist in consideration
and Board adoption of the Company’s strategic plan and annual operating plans, and help promote senior management succession planning. In addition, if requested by the Company’s Board of Directors, the Chairman will assist the
Company’s Chief Executive Officer by advising on acquisition matters, helping to develop programs and actions to reinforce the Company’s core values, providing leadership in the development of the Company’s corporate social
responsibility strategy, acting as a Company spokesperson on issues of corporate social responsibility, and representing the Company at industry conferences, as appropriate. The Chairman will also assist in such other duties and responsibilities
inherent in the position of non-executive Chairman as may reasonably be assigned to him by the Company’s Board of Directors. It is expected that the Chairman will provide services no more than 20 hours each calendar month, in addition to
attendance at Board meetings. 
 5. Compensation. In consideration for the services to be provided during the Chairmanship Period, the
Company shall provide the Chairman with a stipend of Fifty Thousand Dollars ($50,000 annually) (the “Chairmanship Retainer”). In addition, during the Chairmanship Period, the Chairman shall be eligible for the annual Board retainer, all
applicable meeting fees, equity grants, and other benefits available to non-employee directors. During the Chairmanship Period, the Chairman shall be provided with use of an office, either on- or off-site, similar in size to that of other senior
executives of the Company. The Chairman shall be solely responsible for all state and federal income taxes, unemployment insurance and Social Security taxes on the compensation payable pursuant to this Agreement. The Company shall issue to the
Chairman Form 1099 – MISC for the compensation provided to him under this Section annually, in accordance with its regular business practice. It is the express intention of the parties to this Agreement that during the Chairmanship Period, the
Chairman shall not be an employee of the Company for any purposes whatsoever and, therefore, shall not be eligible for or otherwise entitled to (a) any salary, bonuses, or long-term incentive payments; or (b) any benefit programs that the
Company may make available to its employees from time to time. 
 6. Vesting of Equity. On the Transition Date, all options held by
the Chairman to acquire shares of common stock of the Company shall become immediately exercisable and all 

 
restricted stock units under the Long Term Incentive Plan and the Management Stock Purchase Plan shall become fully vested and no longer subject to any risks
of forfeiture. 
 7. Transfer of Country Club Membership. On the Transition Date, the Company shall transfer to the Chairman its
membership interest in The International Golf Club. 
 8. Termination. 
 a. Termination Due to Death. The Chairmanship Period shall terminate immediately upon the death of the Chairman. In the event termination due to
the Chairman’s death occurs, the Chairman’s estate shall not be entitled to any further payments under Section 5 of this Agreement. 
 b. Termination Due to Disability. The Transition Period and the Chairmanship Period shall terminate immediately upon the Disability of the Chairman. In the event termination due to the Chairman’s Disability occurs, the Chairman
shall not be entitled to any further payments under Section 5 of this Agreement. As used in this Agreement, the term “Disability” shall mean the inability of the Chairman to perform the essential functions of his position due to a
physical or mental disability, with or without reasonable accommodation as may be required by state or federal laws for a period of 120 days. A determination of Disability shall be made by a physician chosen by both the Chairman and the Company,
provided that if the Chairman and the Company cannot agree on a physician, the Chairman and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding
on all parties. 
 c. Termination Due To Failure to Be Reelected. The Chairmanship Period shall terminate immediately upon the failure
of the Chairman to secure reelection to the Board by shareholders as a non-employee director. In the event termination under this Section occurs, the Chairman shall not be entitled to any further payments under Section 5 of this Agreement.

 d. Termination by the Chairman. In the event the Chairman chooses to resign his position as a non-executive director during the
Chairmanship Period, he shall provide thirty (30) days’ advance written notice to the Company. In such event, the Chairman shall not be entitled to any further payments and benefits under Section 5 of this Agreement following the
effective date of his resignation. 
 9. Non-Disparagement. During the Transition Period, the Chairmanship Period, and at all times
thereafter, the Chairman agrees that as a condition to the Company’s execution of this Agreement, he shall not make any false, disparaging or derogatory statements in public or private regarding the Company and its current and former officers,
directors, stockholders, agents, employees and attorneys, or regarding the Company’s business affairs, business prospects and financial condition. In consideration of the Chairman’s execution of this Agreement, the Company also agrees not
to make any false, disparaging or derogatory statements in public or private regarding the Chairman. 
 10. Amendment. This Agreement
shall be binding upon the parties and may not be abandoned, supplemented, changed or modified in any manner, orally or otherwise, except by an 

 
instrument in writing of concurrent or subsequent date signed by a duly authorized representative of the parties. 
 11. Validity. Should any provision of this Agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid,
the validity of the remaining parts, terms, or provisions shall not be affected and said illegal and invalid part, term or provision shall be deemed not to be a part of this Agreement. 
 12. Waiver. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion. 
 13. Entire Agreement. As of the Effective Date, this Agreement supersedes all prior agreements, written or oral, between the Chairman and the
Company relating to the subject matter of this Agreement, provided, however, that the Employment Agreement shall remain in effect until the Transition Date. The Employment Agreement shall terminate on the Transition Date, except that Paragraphs 4,
5, 13 and 15 thereof shall survive such termination and shall remain in effect in accordance with their terms. This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Chairman
and the Company. Nothing in this Section shall modify, cancel or supersede the Retirement Plans or the Indemnification Agreement dated November 6, 2002 between the Chairman and the Company, which shall remain in full force and effect.

 14. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective
successors and assigns, including any corporation or entity with which or into which the Company may be merged or which may succeed to its assets or business, provided however that the obligations of the Chairman are personal and shall not be
assigned by the Chairman. The Chairman further expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate. 
 15. Governing Law, Forum and Jurisdiction. This Agreement shall be governed by and construed as a sealed instrument under and in accordance with
the laws of the Commonwealth of Massachusetts (without reference to the conflicts of law provisions thereof). 
 16. Captions. The
captions of the Sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any Section of this Agreement. 
 17. Counterparts. This Agreement may be executed in several counterparts, each of which shall constitute an original, but all of which taken
together shall constitute one and the same instrument. 
 18. Notices. All notices required or permitted under this Agreement shall be
in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address designated herein, or at such other
address or addresses as either party shall designate to the other in writing in accordance with this Section. Notice to the Company shall be 

 
addressed to: Vice President, General Counsel and Secretary, CIRCOR International, Inc., 25 Corporate Drive, Suite 130, Burlington, MA 01803. Notice to the
Chairman shall be addressed to his home address as shown in the Company’s records. 
 WITNESS our hands and seals the date first above written:

  

			
	CIRCOR INTERNATIONAL, INC.	 	CHAIRMAN
		
	By:  /s/ David F. Dietz	 	/s/  David A. Bloss, Sr.
	        David F. Dietz, Director	 	David A. Bloss, Sr.Amendment No. 1 to Employment Agreement with Pierre Etienne, Ph.D.

 Exhibit 10.5.1 
 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT 
 This Amendment No. 1 (the
“Amendment”) is made as of this 8th day of August, 2007, by and between Dr. Pierre Emile G. Etienne (the “Employee”) and Targanta Therapeutics Corporation, a corporation formed under the laws of the State of
Delaware and having its principal place of business in Cambridge, Massachusetts (the “Company”). The Company and the Employee may each hereinafter be referred to as a “Party” and together as the
“Parties” hereto. 
 WHEREAS, the parties are subject to an Employment Agreement dated May 6, 2007 (the “Employment
Agreement”), that sets forth the rights and obligations of the Parties in connection with the Company’s employment of Employee; and 
 WHEREAS, the Parties seek to amend the Employment Agreement as more fully set forth below; 
 NOW, THEREFORE,
in consideration of the foregoing and of the mutual promises and covenants contained herein, the Parties hereto agree as follows: 
 1.
Section 6 of the Employment Agreement is hereby deleted and replaced in its entirety with the following: 
 6.
STOCK OPTIONS. In connection with Employee’s continued employment by the Company, at the next regularly scheduled meeting of the Board of Directors or the Compensation
Committee thereof, the Company will agree to amend the grant of options to purchase 300,000 shares of the Company’s common stock (the “Options”), which grant was made to the Employee on May 7, 2007 pursuant to the
Company’s Amended and Restated 2005 Stock Option Plan (the “Plan”), to provide that the Options shall instead vest as follows: 75,000 of the Options shall be vested upon grant and the remaining Options shall vest quarterly over
three years commencing on the three month anniversary of the date of grant, subject to acceleration in certain circumstances as further described below. The Employee shall be eligible to receive future grants of equity incentives as determined by
the Board of Directors (or the Compensation Committee thereof) in its sole discretion. The Employee acknowledges that the Options were issued in replacement of the options previously granted to Employee pursuant to (i) that certain Stock Option
Agreement dated July 10, 2003, between the Employee and Targanta Therapeutics, Inc. (f/k/a PhageTech, Inc.), a Canadian corporation and subsidiary of the Company (“Targanta Quebec”), for 919,656 common exchangeable shares of
Targanta Quebec at an exercise price of $0.38 CDN (following the 150:1 reverse stock split, now exercisable for 61,310 shares at an exercise price of $57.00 CDN per share); and (ii) that certain Notice of Stock Option Grant dated March 29, 2006,
between the Company and Employee for 400,000 shares of the Company’s common stock at an exercise price of $0.24 US (following the 150:1 reverse stock split, now 

 
exercisable for 2,667 shares at an exercise price of $36.00 US per share), which options the Employee previously agreed to tender to the Company for
cancellation in exchange for the receipt of the Options described above. 
 2. The following is added as a new Section 10(g) of the
Employment Agreement: 
 (f) Definition of Good Reason. For purposes of this Agreement, “Good
Reason” means (i) the failure of the Company to employ Employee in his current or a substantially similar position with the same reporting relationship, without regard to title, such that his duties and responsibilities are materially
diminished without his written consent (provided that he notifies the Company in writing of such diminution of duties within 45 days of the diminution); (ii) a reduction in Employee’s Base Salary and/or target annual Bonus without his
written consent (unless such reduction is in connection with a proportional reduction in compensation to all or substantially all of the Company’s employees); or (iii) a requirement that Employee relocate his permanent personal residence to a
location outside of the geographic vicinity of the Company’s present corporate headquarters, except that it shall not be Good Reason for Employee to terminate his employment if the Company continues to provide Employee with either a company
apartment in substantially the same manner as it does at the time the Parties execute this Amendment or other reasonable company-paid accommodations in any remote location where Employee is required to regularly perform services for the Company.

 3. Section 10(c) of the Employment Agreement shall be deleted and replaced with the following: 
 Severance Benefits Following a Change of Control. In the event that, within twenty four (24) months following a Change of
Control, Employee’s employment is terminated without Cause or as a result of death or Disability, or if Employee resigns for Good Reason, then, in addition to the payments described in Section 10(a), Employee shall be entitled to receive the
Severance Benefits, subject to the conditions otherwise set forth in the Employment Agreement including, without limitation, Section 10(d). 
 4. This Amendment may be executed in one or more counterparts and with counterpart facsimile signature pages, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same agreement.

 5. This Amendment shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without
regard to its conflicts of law principles. Any proceeding arising out of or relating to this Amendment may be brought in the state or federal courts located in the Commonwealth of Massachusetts. 
 6. All other aspects of the Employment Agreement shall remain unchanged and in full force and effect. 

 IN WITNESS WHEREOF, the Parties have, on the following page, executed and sealed this Agreement on the
day and year first above written. 
  

									
	 TARGANTA THERAPEUTICS
 CORPORATION
	 		 	
					
	By:	 	/s/ George Eldridge	 		 		 	/s/ Pierre Emile G. Etienne
		 	Name: George Eldridge	 		 		 	Dr. Pierre Emile G. Etienne
		 	Title: Chief Financial Officer	 		 		 	
			
	Date: August 8, 2007	 		 	Date: August 9, 2007
			
	Witnessed: Lee Merrill	 		 	Witnessed: Nicole Etienne

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]